Widespread Detection of VEB-1-Type Extended-Spectrum Beta-Lactamases Among Nosocomial Ceftazidime-Resistant<i>Pseudomonas aeruginosa</i>Isolates in Sofia, Bulgaria

Strateva, Tanya; Ouzounova-Raykova, V.; Markova, Boyka; Тодорова, Албена; Marteva-Proevska, Yulia; Mitov, Ivan

doi:10.1179/joc.2007.19.2.140

Cited by 17 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEB-type ESBLs were the predominant ESBL reported in P. aeruginosa in a number of studies where ESBLs were commonly seen (Jiang et al, 2006; Strateva et al, 2007; Woodford et al, 2008; Shahcheraghi et al, 2009) although PER-type ESBLs were also well-represented (Celenza et al, 2006; Endimiani et al, 2006; Shahcheraghi et al, 2009; Glupczynski et al, 2010). While BEL-1 (Poirel et al, 2005; Bogaerts et al, 2007) and CTX-M (al Naiemi et al, 2006; Picao et al, 2009b) ESBLs are not frequently observed in P. aeruginosa , they were the predominant ESBLs reported in ESBL + P. aeruginosa in a Belgium study (Glupczynski et al, 2010) and a Bolivian study (Celenza et al, 2006), respectively.…”

Section: Resistance To β-Lactamsmentioning

confidence: 99%

“…Class A ESBLs are typically identified in P. aeruginosa isolates showing resistance to ceftazidime (e.g., De Champs et al, 2002; Girlich et al, 2002; Strateva et al, 2007; Hocquet et al, 2010]. VEB-type ESBLs were the predominant ESBL reported in P. aeruginosa in a number of studies where ESBLs were commonly seen (Jiang et al, 2006; Strateva et al, 2007; Woodford et al, 2008; Shahcheraghi et al, 2009) although PER-type ESBLs were also well-represented (Celenza et al, 2006; Endimiani et al, 2006; Shahcheraghi et al, 2009; Glupczynski et al, 2010).…”

Section: Resistance To β-Lactamsmentioning

confidence: 99%

See 1 more Smart Citation

Pseudomonas Aeruginosa: Resistance to the Max

Poole¹

2011

Front. Microbio.

752

654

View full text Add to dashboard Cite

Pseudomonas aeruginosa is intrinsically resistant to a variety of antimicrobials and can develop resistance during anti-pseudomonal chemotherapy both of which compromise treatment of infections caused by this organism. Resistance to multiple classes of antimicrobials (multidrug resistance) in particular is increasingly common in P. aeruginosa, with a number of reports of pan-resistant isolates treatable with a single agent, colistin. Acquired resistance in this organism is multifactorial and attributable to chromosomal mutations and the acquisition of resistance genes via horizontal gene transfer. Mutational changes impacting resistance include upregulation of multidrug efflux systems to promote antimicrobial expulsion, derepression of ampC, AmpC alterations that expand the enzyme's substrate specificity (i.e., extended-spectrum AmpC), alterations to outer membrane permeability to limit antimicrobial entry and alterations to antimicrobial targets. Acquired mechanisms contributing to resistance in P. aeruginosa include β-lactamases, notably the extended-spectrum β-lactamases and the carbapenemases that hydrolyze most β-lactams, aminoglycoside-modifying enzymes, and 16S rRNA methylases that provide high-level pan-aminoglycoside resistance. The organism's propensity to grow in vivo as antimicrobial-tolerant biofilms and the occurrence of hypermutator strains that yield antimicrobial resistant mutants at higher frequency also compromise anti-pseudomonal chemotherapy. With limited therapeutic options and increasing resistance will the untreatable P. aeruginosa infection soon be upon us?

show abstract

Section: Resistance To β-Lactamsmentioning

confidence: 99%

Section: Resistance To β-Lactamsmentioning

confidence: 99%

Pseudomonas Aeruginosa: Resistance to the Max

Poole¹

2011

Front. Microbio.

752

654

View full text Add to dashboard Cite

show abstract

“…Similar pattern had been reported in study in Nigeria 47 . In addition, susceptibility to fourth-generation such as cefepime reported in India 32% 48 and in Bulgaria 42% 49 against Pseudomonas aeruginosa isolates. The high resistance to cephalosporins may be due to production of extended spectrum β-lactamases by the bacteria involved 50 .…”

Section: Figure 4: Distribution Of P Aeruginosa Isolates According Tmentioning

confidence: 99%

Prevalence of Pseudomonas Aeruginosa (P. Aeruginosa) and Antimicrobial Susceptibility Patterns at a Private Hospital in Sana'a, Yemen

2018

View full text Add to dashboard Cite

Objective: Pseudomonas aeruginosa is clinically significant and opportunistic pathogen that causes infections in hospitalized patients. Antibiotic resistance is a major concern in clinical practice. The ongoing emergence of resistant strains that cause nosocomial infections contributes substantially to the morbidity and mortality of hospitalized patients. Objective of present study was to estimate the prevalence of Pseudomonas aeruginosa and the antimicrobial resistance patterns of P. aeruginosa isolates from hospitalized patients. Methods: The study was performed at microbiology department of a local hospital in Sana'a, Yemen. All the patients' samples of hospital departments from January, 2017 to December, 2017 were included. A Total of 2079 samples were collected during the study period. Among them, 193 strains of Pseudomonas spp. were isolated. One hundred ninety three isolates of P. aeruginosa were isolated from different clinical specimens and fully characterized by standard bacteriological procedures. Antimicrobial susceptibility pattern of each isolates was carried out by the Kirby-Bauer disk diffusion method as per CLSI guidelines. Majority of P. aeruginosa were isolated from Sputum, followed by urine specimens. Results: The isolate pathogen showed the highest sensitive to Meropenem (85.5%), followed by Amikacin (80.5%), Imipenem (80.0%), and Piperacillin/tazobactam (77.2). The highest frequency of resistance (96.2%) was observed with amoxicillin /clavulinic Acid followed by cefuroxime 94.6%, ampicillin/ sulbactam 94.5%, Co-Trimoxzole 80.5%, and norfloxacin 54%. Conclusion: The result confirmed the occurrence of drug resistance strains of P. aeruginosa. Meropenem, imipenem, and amikacin, were found to be the most effective antimicrobial drugs. It therefore calls for a very judicious, appropriate treatment regimens selection by the physicians to limit the further spread of antimicrobial resistance P. aeruginosa.

show abstract

“…Nosocomial spread of VEB-1-producing P. aeruginosa isolates was identified in Thailand [54]. Later, other VEB-like producing isolates were reported from Kuwait and India [55,56], but also in Iran, Bulgaria, the UK and Denmark, highlighting the worldwide dissemination of these VEBproducing strains [12,[57][58][59] (Table 1). Isolates producing VEB-2 or VEB-3 were identified in Thailand and China, with these ESBLs differing from VEB-1 by only a single or two amino acid substitutions, respectively [54,60].…”

Section: Extended-spectrum ˇ-Lactamases (Esbls)mentioning

confidence: 99%

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

Potron

Poirel

Nordmann

2015

International Journal of Antimicrobial Agents

606

460

View full text Add to dashboard Cite

Multidrug resistance is quite common among non-fermenting Gram-negative rods, in particular among clinically relevant species including Pseudomonas aeruginosa and Acinetobacter baumannii. These bacterial species, which are mainly nosocomial pathogens, possess a diversity of resistance mechanisms that may lead to multidrug or even pandrug resistance. Extended-spectrum ␤-lactamases (ESBLs) conferring resistance to broad-spectrum cephalosporins, carbapenemases conferring resistance to carbapenems, and 16S rRNA methylases conferring resistance to all clinically relevant aminoglycosides are the most important causes of concern. Concomitant resistance to fluoroquinolones, polymyxins (colistin) and tigecycline may lead to pandrug resistance. The most important mechanisms of resistance in P. aeruginosa and A. baumannii and their most recent dissemination worldwide are detailed here.

show abstract

Widespread Detection of VEB-1-Type Extended-Spectrum Beta-Lactamases Among Nosocomial Ceftazidime-ResistantPseudomonas aeruginosaIsolates in Sofia, Bulgaria

Cited by 17 publications

References 21 publications

Pseudomonas Aeruginosa: Resistance to the Max

Pseudomonas Aeruginosa: Resistance to the Max

Prevalence of Pseudomonas Aeruginosa (P. Aeruginosa) and Antimicrobial Susceptibility Patterns at a Private Hospital in Sana'a, Yemen

Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology

Contact Info

Product

Resources

About